These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

165 related items for PubMed ID: 17144663

  • 1. Transmembrane segment peptides can disrupt cholecystokinin receptor oligomerization without affecting receptor function.
    Harikumar KG, Dong M, Cheng Z, Pinon DI, Lybrand TP, Miller LJ.
    Biochemistry; 2006 Dec 12; 45(49):14706-16. PubMed ID: 17144663
    [Abstract] [Full Text] [Related]

  • 2. Agonist-dependent dissociation of oligomeric complexes of G protein-coupled cholecystokinin receptors demonstrated in living cells using bioluminescence resonance energy transfer.
    Cheng ZJ, Miller LJ.
    J Biol Chem; 2001 Dec 21; 276(51):48040-7. PubMed ID: 11673456
    [Abstract] [Full Text] [Related]

  • 3. A peptide agonist acts by occupation of a monomeric G protein-coupled receptor: dual sites of covalent attachment to domains near TM1 and TM7 of the same molecule make biologically significant domain-swapped dimerization unlikely.
    Hadac EM, Ji Z, Pinon DI, Henne RM, Lybrand TP, Miller LJ.
    J Med Chem; 1999 Jun 17; 42(12):2105-11. PubMed ID: 10377216
    [Abstract] [Full Text] [Related]

  • 4. Intermolecular interactions between cholecystokinin-8 and the third extracellular loop of the cholecystokinin A receptor.
    Giragossian C, Mierke DF.
    Biochemistry; 2001 Apr 03; 40(13):3804-9. PubMed ID: 11300760
    [Abstract] [Full Text] [Related]

  • 5. Fluorescence studies on the binding between 1-47 fragment of cholecystokinin receptor CCK(A)-R(1-47) and nonsulfated cholecystokinin octapeptide CCK8.
    Ragone R, De Luca S, Tesauro D, Pedone C, Morelli G.
    Biopolymers; 2001 Apr 03; 56(1):47-53. PubMed ID: 11582577
    [Abstract] [Full Text] [Related]

  • 6. Effects of cholecystokinin-58 on type 1 cholecystokinin receptor function and regulation.
    Wu SV, Harikumar KG, Burgess RJ, Reeve JR, Miller LJ.
    Am J Physiol Gastrointest Liver Physiol; 2008 Sep 03; 295(3):G641-7. PubMed ID: 18776046
    [Abstract] [Full Text] [Related]

  • 7. Ligand-induced internalization of cholecystokinin receptors. Demonstration of the importance of the carboxyl terminus for ligand-induced internalization of the rat cholecystokinin type B receptor but not the type A receptor.
    Pohl M, Silvente-Poirot S, Pisegna JR, Tarasova NI, Wank SA.
    J Biol Chem; 1997 Jul 18; 272(29):18179-84. PubMed ID: 9218453
    [Abstract] [Full Text] [Related]

  • 8. Identification of two amino acids of the human cholecystokinin-A receptor that interact with the N-terminal moiety of cholecystokinin.
    Kennedy K, Gigoux V, Escrieut C, Maigret B, Martinez J, Moroder L, Fréhel D, Gully D, Vaysse N, Fourmy D.
    J Biol Chem; 1997 Jan 31; 272(5):2920-6. PubMed ID: 9006937
    [Abstract] [Full Text] [Related]

  • 9. Measurement of intermolecular distances for the natural agonist Peptide docked at the cholecystokinin receptor expressed in situ using fluorescence resonance energy transfer.
    Harikumar KG, Pinon DI, Wessels WS, Dawson ES, Lybrand TP, Prendergast FG, Miller LJ.
    Mol Pharmacol; 2004 Jan 31; 65(1):28-35. PubMed ID: 14722234
    [Abstract] [Full Text] [Related]

  • 10. Arginine 197 of the cholecystokinin-A receptor binding site interacts with the sulfate of the peptide agonist cholecystokinin.
    Gigoux V, Maigret B, Escrieut C, Silvente-Poirot S, Bouisson M, Fehrentz JA, Moroder L, Gully D, Martinez J, Vaysse N, Fourmy AD.
    Protein Sci; 1999 Nov 31; 8(11):2347-54. PubMed ID: 10595537
    [Abstract] [Full Text] [Related]

  • 11. Conserved cholecystokinin receptor transmembrane domain IV amino acids confer peptide affinity.
    Ren Y, Bläker M, Seshadri L, McBride EW, Beinborn M, Kopin AS.
    J Mol Neurosci; 2003 Apr 31; 20(2):115-24. PubMed ID: 12794305
    [Abstract] [Full Text] [Related]

  • 12. Transmembrane segment IV contributes a functionally important interface for oligomerization of the Class II G protein-coupled secretin receptor.
    Harikumar KG, Pinon DI, Miller LJ.
    J Biol Chem; 2007 Oct 19; 282(42):30363-72. PubMed ID: 17726027
    [Abstract] [Full Text] [Related]

  • 13. CCK-B/Gastrin receptor transmembrane domain mutations selectively alter synthetic agonist efficacy without affecting the activity of endogenous peptides.
    Bläker M, Ren Y, Seshadri L, McBride EW, Beinborn M, Kopin AS.
    Mol Pharmacol; 2000 Aug 19; 58(2):399-406. PubMed ID: 10908308
    [Abstract] [Full Text] [Related]

  • 14. Molecular complex of cholecystokinin-8 and N-terminus of the cholecystokinin A receptor by NMR spectroscopy.
    Pellegrini M, Mierke DF.
    Biochemistry; 1999 Nov 09; 38(45):14775-83. PubMed ID: 10555959
    [Abstract] [Full Text] [Related]

  • 15. On the biologically active structures of cholecystokinin, little gastrin, and enkephalin in the gastrointestinal system.
    Pincus MR, Carty RP, Chen J, Lubowsky J, Avitable M, Shah D, Scheraga HA, Murphy RB.
    Proc Natl Acad Sci U S A; 1987 Jul 09; 84(14):4821-5. PubMed ID: 3037525
    [Abstract] [Full Text] [Related]

  • 16. Photoaffinity labeling of rat pancreatic cholecystokinin type A receptor antagonist binding sites demonstrates the presence of a truncated cholecystokinin type A receptor.
    Poirot SS, Escrieut C, Dufresne M, Martinez J, Bouisson M, Vaysse N, Fourmy D.
    Mol Pharmacol; 1994 Apr 09; 45(4):599-607. PubMed ID: 8183238
    [Abstract] [Full Text] [Related]

  • 17. Identification of cholecystokinin-B/gastrin receptor domains that confer high gastrin affinity: utilization of a novel Xenopus laevis cholecystokinin receptor.
    Schmitz F, Pratt DS, Wu MJ, Kolakowski LF, Beinborn M, Kopin AS.
    Mol Pharmacol; 1996 Aug 09; 50(2):436-41. PubMed ID: 8700154
    [Abstract] [Full Text] [Related]

  • 18. Functional importance of a structurally distinct homodimeric complex of the family B G protein-coupled secretin receptor.
    Gao F, Harikumar KG, Dong M, Lam PC, Sexton PM, Christopoulos A, Bordner A, Abagyan R, Miller LJ.
    Mol Pharmacol; 2009 Aug 09; 76(2):264-74. PubMed ID: 19429716
    [Abstract] [Full Text] [Related]

  • 19. The use of topographical constraints in receptor mapping: investigation of the topographical requirements of the tryptophan 30 residue for receptor binding of Asp-Tyr-D-Phe-Gly-Trp-(N-Me)Nle-Asp-Phe-NH2 (SNF 9007), a cholecystokinin (26-33) analogue that binds to both CCK-B and delta-opioid receptors.
    Boteju LW, Nikiforovich GV, Haskell-Luevano C, Fang SN, Zalewska T, Stropova D, Yamamura HI, Hruby VJ.
    J Med Chem; 1996 Sep 27; 39(20):4120-4. PubMed ID: 8831778
    [Abstract] [Full Text] [Related]

  • 20. Ligand-induced internalization of the type 1 cholecystokinin receptor independent of recognized signaling activity.
    Cawston EE, Harikumar KG, Miller LJ.
    Am J Physiol Cell Physiol; 2012 Feb 01; 302(3):C615-27. PubMed ID: 22049215
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.